Immuneering To Be Added To Nasdaq Biotechnology Index, Effective December 22

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index ("NBI") (NASDAQ:NBI). Immuneering's addition will become effective prior to market open on Monday, December 22, 2025.